Trials / Completed
CompletedNCT05107128
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 189 (actual)
- Sponsor
- Supernus Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAGE-718 | Oral capsules. |
| DRUG | Placebo | SAGE-718-matching oral capsules. |
Timeline
- Start date
- 2022-01-26
- Primary completion
- 2024-09-04
- Completion
- 2024-10-03
- First posted
- 2021-11-04
- Last updated
- 2025-09-15
- Results posted
- 2025-09-05
Locations
49 sites across 4 countries: United States, Australia, Canada, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05107128. Inclusion in this directory is not an endorsement.